Total Payments
$120,319
2024 Payments
$11,526
Companies
21
Transactions
106
Medicare Patients
10,687
Medicare Billing
$4.6M
Payment Breakdown by Category
Consulting$71,568 (59.5%)
Research$28,457 (23.7%)
Other$9,745 (8.1%)
Travel$8,773 (7.3%)
Food & Beverage$1,617 (1.3%)
Education$159.14 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $71,568 | 30 | 59.5% |
| Unspecified | $28,457 | 1 | 23.7% |
| Travel and Lodging | $8,773 | 27 | 7.3% |
| Honoraria | $8,110 | 4 | 6.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,635 | 2 | 1.4% |
| Food and Beverage | $1,617 | 37 | 1.3% |
| Education | $159.14 | 5 | 0.1% |
Payments by Type
General
$91,862
105 transactions
Research
$28,457
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Rigel Pharmaceuticals, Inc. | $29,657 | 2 | $0 (2022) |
| Gilead Sciences, Inc. | $16,077 | 26 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $15,802 | 18 | $0 (2024) |
| ABBVIE INC. | $10,916 | 27 | $0 (2022) |
| Millennium Pharmaceuticals, Inc. | $10,187 | 8 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $8,739 | 4 | $0 (2018) |
| PFIZER INC. | $5,910 | 3 | $0 (2022) |
| Kite Pharma, Inc. | $5,300 | 4 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $2,756 | 2 | $0 (2024) |
| Deciphera Pharmaceuticals Inc. | $2,200 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,526 | 12 | Gilead Sciences, Inc. ($6,236) |
| 2023 | $3,339 | 4 | AstraZeneca Pharmaceuticals LP ($1,756) |
| 2022 | $45,953 | 23 | Rigel Pharmaceuticals, Inc. ($28,457) |
| 2021 | $18,732 | 13 | PFIZER INC. ($4,410) |
| 2020 | $7,075 | 4 | Deciphera Pharmaceuticals Inc. ($2,200) |
| 2019 | $4,425 | 8 | Gilead Sciences, Inc. ($4,425) |
| 2018 | $12,968 | 23 | Takeda Pharmaceuticals U.S.A., Inc. ($8,739) |
| 2017 | $16,300 | 19 | Millennium Pharmaceuticals, Inc. ($10,187) |
All Payment Transactions
106 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,230.00 | General |
| 11/18/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $435.00 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 04/16/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $5,240.00 | General |
| Category: ONC | ||||||
| 04/11/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: ONC | ||||||
| 04/11/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $47.15 | General |
| Category: ONC | ||||||
| 04/11/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $42.86 | General |
| Category: ONC | ||||||
| 04/10/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $541.20 | General |
| Category: ONC | ||||||
| 04/10/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: ONC | ||||||
| 04/10/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $88.27 | General |
| Category: ONC | ||||||
| 02/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: Oncology | ||||||
| 11/28/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| Category: Oncology | ||||||
| 06/23/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $43.91 | General |
| 02/16/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Education | In-kind items and services | $19.99 | General |
| Category: CELLT | ||||||
| 01/09/2023 | Seagen Inc. | PADCEV (Biological) | Consulting Fee | Cash or cash equivalent | $1,562.50 | General |
| Category: Oncology | ||||||
| 12/09/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $4,270.00 | General |
| Category: ONC | ||||||
| 11/14/2022 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| Category: Oncology | ||||||
| 11/07/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $17.10 | General |
| Category: ONC | ||||||
| 11/05/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $394.60 | General |
| Category: ONC | ||||||
| 11/05/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $36.52 | General |
| Category: ONC | ||||||
| 11/05/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $36.52 | General |
| Category: ONC | ||||||
| 11/05/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $35.87 | General |
| Category: ONC | ||||||
| 11/05/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $24.00 | General |
| Category: ONC | ||||||
| 11/04/2022 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Rigel Pharmaceuticals, Inc. | $28,457 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 670 | 1,883 | $478,974 | $125,263 |
| 2022 | 31 | 2,657 | 33,951 | $1.2M | $284,112 |
| 2021 | 36 | 2,879 | 69,414 | $2.1M | $497,074 |
| 2020 | 61 | 4,481 | 304,211 | $10.6M | $3.7M |
Total Patients
10,687
Total Services
409,459
Medicare Billing
$4.6M
Procedure Codes
149
All Medicare Procedures & Services
149 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 542 | 1,720 | $435,732 | $117,028 | 26.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 20 | 20 | $12,590 | $2,752 | 21.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 45 | $14,108 | $2,723 | 19.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 18 | 19 | $10,673 | $2,083 | 19.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 28 | 32 | $2,710 | $243.52 | 9.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 23 | 27 | $858.60 | $226.80 | 26.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 19 | 20 | $2,304 | $207.00 | 9.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 395 | 1,101 | $260,934 | $78,187 | 30.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2022 | 20 | 28,100 | $224,122 | $71,414 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 187 | 446 | $139,735 | $38,741 | 27.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 20 | 107 | $49,236 | $15,312 | 31.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 42 | 128 | $89,135 | $13,311 | 14.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 363 | 763 | $82,151 | $7,969 | 9.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 401 | 953 | $75,439 | $7,320 | 9.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 78 | 78 | $37,674 | $7,148 | 19.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 95 | 110 | $22,847 | $6,880 | 30.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 120 | 146 | $30,272 | $6,281 | 20.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 36 | 108 | $32,054 | $5,887 | 18.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $14,490 | $2,784 | 19.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 13 | 49 | $16,013 | $2,521 | 15.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 371 | 850 | $25,245 | $2,521 | 10.0% |
| 36591 | Collection of blood sample from implanted device | Office | 2022 | 49 | 102 | $23,725 | $2,020 | 8.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 22 | 42 | $15,665 | $2,017 | 12.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 17 | 17 | $7,599 | $1,786 | 23.5% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2022 | 41 | 86 | $16,788 | $1,567 | 9.3% |
About Dr. Adedayo Onitilo, MD
Dr. Adedayo Onitilo, MD is a Hematology & Oncology healthcare provider based in Weston, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275631566.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adedayo Onitilo, MD has received a total of $120,319 in payments from pharmaceutical and medical device companies, with $11,526 received in 2024. These payments were reported across 106 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($71,568).
As a Medicare-enrolled provider, Onitilo has provided services to 10,687 Medicare beneficiaries, totaling 409,459 services with total Medicare billing of $4.6M. Data is available for 4 years (2020–2023), covering 149 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Weston, WI
- Active Since 09/20/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1275631566
Products in Payments
- Tavalisse (Drug) $29,657
- Trodelvy (Drug) $11,629
- NINLARO (Drug) $10,046
- ALUNBRIG (Drug) $8,739
- IMFINZI (Drug) $6,041
- IMFINZI (Biological) $4,510
- TAGRISSO (Drug) $3,425
- Tecartus (Drug) $3,300
- VENCLEXTA (Drug) $3,264
- Venclexta (Drug) $2,363
- QINLOCK (Drug) $2,200
- Yescarta (Drug) $2,000
- MONJUVI (Drug) $1,770
- TECENTRIQ (Biological) $1,740
- PADCEV (Biological) $1,563
- XPOVIO (Drug) $1,550
- FOTIVDA (Drug) $1,500
- NERLYNX (Drug) $1,000
- Vitrakvi (Drug) $900.00
- Truqap (Drug) $525.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Weston
Dr. Chakra Chaulagain, Md, MD
Hematology & Oncology — Payments: $172,661
Hematology & Oncology $172,661
Chieh-Lin Fu, M.d, M.D
Hematology & Oncology — Payments: $16,690
Hematology & Oncology $16,690
Evan Alley, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $10,998
Hematology & Oncology $10,998
Dr. Arun Nagarajan, Md, MD
Hematology & Oncology — Payments: $5,171
Hematology & Oncology $5,171
Tiffany George, Md, MD
Hematology & Oncology — Payments: $3,921
Hematology & Oncology $3,921
Dr. Diana Saravia, M.d, M.D
Hematology & Oncology — Payments: $3,022
Hematology & Oncology $3,022